
Virology Market
Description
Virology Market
Virology, the study of viruses, is an unparalleled branch of life sciences. With immensely high prevalence of diseases such as flu, hepatitis, AIDS, and STDs, the importance of virology is repeatedly highlighted. The global virology market is expected to grow over 2015-2025.
FMI’s research identifies growing infectious diseases as a key force driving the market throughout the forecast period.
Key Drivers: Virology Market
Early in 2016, the WHO officially issued a warning about the possible spread of zika virus to each Western Hemispheric region, as the disease vector Aedes aegypti was found to thrive strong in tropical and sub-tropical climatic conditions. This has been a key driver of market growth throughout 2016.
The virology market is constantly catering to the prevention and cure needs put forth by the healthcare sector; however, several diseases continue to demand R&D of novel applications, driving the growth of virology market. Various treatments and diagnostic processes also employ virology applications, further fuelling the market growth.
Burgeoning applications of virology research in gene therapy, phage therapy, formulation of vaccines, and synthetic biology is another factor fostering the overall growth of the virology market.
Moreover, the field of virology is extending in various forms, including molecular virology, paediatric virology, computational virology, and many more, prompting at increasing research findings throughout the forecast period. Research prospects are high and FMI indicates a continuing need for trained virologists in the near future.
Public awareness programmes conducted worldwide on flu, zika virus, STDs, AIDS, and Ebola virus are also a key factor increasing public awareness and eventually influencing the market.
Key Restraints to Market Growth
Maintaining the quality and safety standards of viral a controlling therapy has been a longstanding challenge, which is anticipated to hamper the market in the forecast period as well. Moreover, stringent approval processes for antiviral drugs is also foreseen to be a restraint to market growth. Another factor identified for affecting the market growth includes resistance toward and side effects of antiviral drugs for new treatment options.
Current Trends in the Virology Field
In 2015, the virology industry was predominantly influenced by ebola, MERS, and hepatitis C viruses. In 2016, zika virus is dominating the research, with better prospects in the near future.
Virologists are persistently investigating novel applications for viruses. Currently, an ongoing research is experimenting on the exploitation of viruses for plant production, aiming at the efficient production of high quality, eco-friendly food.
Global Virology Market: Competitive Landscape
By 2017 end, a few important patents are approaching expiry, including Tamiflu, Sustiva, Tenofovir, Combivir, Relenza, and Telbivudine. Following expiry of these blockbuster drugs, the market is estimated to discover a dynamic competitive landscape. The generic competition in the virology market will be at a high pace 2017 onward.
Apart from expiring drugs, the market also has some late stage pipeline drugs, including Inavir, Elvitegravir, Vicriviroc, Rilpivirine, and Rapiacta. These drugs are set to enter the global market, fostering the competition globally.
Virology Market: Segmentation
FMI's research on the global virology market provides a 10-year forecast, segmenting the market on the basis of product type, application, end-use, and region.
Based on product type, the global virology market is segmented into
Diagnosing Test
DNA Viruses
RNA Viruses
Prions Diagnostic Test
Other Viral Tests
Viral Infection Controlling Methods
Immunoprophylaxis
Active Prophylaxis (Vaccines)
Passive Prophylaxis
Antiviral Chemotherapy
Virucidal Agents
Antiviral Agents
Immunomodulators
Interferons
Cytokines
Based on application, the global virology market is segmented into
Skin and Soft Tissue Infections
Respiratory Tract Infections
GI Tract Infections
Urinary Tract Infections
Eye Infections
CNS Infections
Sexually Transmitted Diseases
Perinatal Infections
According to the end-user, the market is segmented into
Hospitals
Clinics
Laboratories
Diagnostic Centres
Blood Banks
Pharmacies
Regional Outlook: Global Virology Market
North America is the largest virology market led by the U.S., owing to technological advancements such as rapid, portable diagnostics. N. America is expected to retain the top market position over the forecast period as well.
Europe is projected to maintain the position as the second largest market globally. During the forecast period, Europe is anticipated to record the highest CAGR, attributed by enhanced healthcare infrastructure, facilitated access to diagnostics, and growing affordability of diagnostic tests for viral diseases.
Japan is currently a growing virology market, which is estimated to grow at a remarkable CAGR through to 2025. However, APEJ and Africa are expected to witness the most promising growth opportunities during the forecast period. While China will be a leading APEJ market, India will contribute a considerable revenue share to the APEJ virology market.
Segment-wise Market Forecast
Immunoprophylaxis therapy and antiviral drugs are the fastest-growing market segments in the estimated forecast period.
STDs, urinary tract infections, and respiratory tract infections are currently dominating compared to other application types in the global virology market.
On the basis of diagnosis tests, hepatitis B, hepatitis C, HIV, human papillomavirus (HPV), and other tests (influenza, ebola, and dengue) are estimated to attract the largest market shares globally.
Hospitals and laboratories projected to continue the most dominating end-use segments, accounting for almost 50% market share globally.
Key Players in the Global Virology Market
The notable players identified in the global virology market include GlaxoSmithKline plc, Abbott Laboratories, Boehringer Ingelheim Corporation, Merck and Co. Inc., Novartis International AG, Siemens, Johnson & Johnson, AstraZeneca AB, and Roche.
Merck and Co. Inc. has several drug candidates in phase 2, including cancer, diabetes, cardiac arrest, and hepatitis C, and some candidates in phase 3, including breast cancer, atherosclerosis, Alzeimer's, ebola, and HIV. The company also has many other candidates, which are currently under review.
Abivax, a high profile biotech company in Paris, France, has already successfully produced candidates against dengue and chikungunya viruses. The company has a few more candidates against HIV and ebola, currently under development.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, accessories and applications.
The report covers exhaustive analysis on:
Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes
North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, BENELUX)
Eastern Europe (Poland, Russia)
Asia Pacific (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC and S. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Report Highlights:
Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.
Table of Contents
250 Pages
- 1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand-side Trends
- 1.3. Supply-side Trends
- 1.4. Technology Roadmap Analysis
- 1.5. Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 3. Market Background
- 3.1. Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Restraints
- 3.1.3. Opportunity
- 3.1.4. Trends
- 3.2. Scenario Forecast
- 3.2.1. Demand in Optimistic Scenario
- 3.2.2. Demand in Likely Scenario
- 3.2.3. Demand in Conservative Scenario
- 3.3. Opportunity Map Analysis
- 3.4. Product Life Cycle Analysis
- 3.5. Supply Chain Analysis
- 3.5.1. Supply Side Participants and their Roles
- 3.5.1.1. Producers
- 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
- 3.5.1.3. Wholesalers and Distributors
- 3.5.2. Value Added and Value Created at Node in the Supply Chain
- 3.5.3. List of Raw Material Suppliers
- 3.5.4. List of Existing and Potential Buyer’s
- 3.6. Investment Feasibility Matrix
- 3.7. Value Chain Analysis
- 3.7.1. Profit Margin Analysis
- 3.7.2. Wholesalers and Distributors
- 3.7.3. Retailers
- 3.8. PESTLE and Porter’s Analysis
- 3.9. Regulatory Landscape
- 3.9.1. By Key Regions
- 3.9.2. By Key Countries
- 3.10. Regional Parent Market Outlook
- 3.11. Production and Consumption Statistics
- 3.12. Import and Export Statistics
- 4. Global Virology Market Analysis 2017-2021 and Forecast, 2022-2032
- 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
- 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
- 4.2.1. Y-o-Y Growth Trend Analysis
- 4.2.2. Absolute $ Opportunity Analysis
- 5. Global Virology Market Analysis 2017-2021 and Forecast 2022-2032, By Product Type
- 5.1. Introduction / Key Findings
- 5.2. Historical Market Size Value (US$ Mn) Analysis By Product Type, 2017-2021
- 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product Type, 2022-2032
- 5.3.1. Instruments
- 5.3.2. Assay Kits
- 5.3.3. Consumables & Accessories
- 5.3.4. Software & Data Management
- 5.3.5. Others
- 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017-2021
- 5.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032
- Deep-dive segmentation will be available in the sample on request
- 6. Global Virology Market Analysis 2017-2021 and Forecast 2022-2032, By Application
- 6.1. Introduction / Key Findings
- 6.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2017-2021
- 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2022-2032
- 6.3.1. Disease Diagnosis
- 6.3.2. Pharmaceuticals
- 6.3.3. Virology Research
- 6.3.4. Others
- 6.4. Y-o-Y Growth Trend Analysis By Application, 2017-2021
- 6.5. Absolute $ Opportunity Analysis By Application, 2022-2032
- Deep-dive segmentation will be available in the sample on request
- 7. Global Virology Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
- 7.1. Introduction / Key Findings
- 7.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2017-2021
- 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2022-2032
- 7.3.1. Skin and Soft Tissue Infections
- 7.3.2. Respiratory Tract Infections
- 7.3.3. GI Tract Infections
- 7.3.4. Urinary Tract Infections
- 7.3.5. Eye Infections
- 7.3.6. CNS Infections
- 7.3.7. Sexually Transmitted Diseases
- 7.3.8. Perinatal Infections
- 7.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021
- 7.5. Absolute $ Opportunity Analysis By Indication, 2022-2032
- Deep-dive segmentation will be available in the sample on request
- 8. Global Virology Market Analysis 2017-2021 and Forecast 2022-2032, By End User
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021
- 8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032
- 8.3.1. Hospitals
- 8.3.2. Clinics
- 8.3.3. Laboratories
- 8.3.4. Diagnostic Centers
- 8.3.5. Blood Banks
- 8.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021
- 8.5. Absolute $ Opportunity Analysis By End User, 2022-2032
- Deep-dive segmentation will be available in the sample on request
- 9. Global Virology Market Analysis 2017-2021 and Forecast 2022-2032, By Region
- 9.1. Introduction
- 9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
- 9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
- 9.3.1. North America
- 9.3.2. Latin America
- 9.3.3. Europe
- 9.3.4. East Asia
- 9.3.5. South Asia & Pacific
- 9.3.6. MEA
- 9.4. Market Attractiveness Analysis By Region
- 10. North America Virology Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
- 10.2.1. By Country
- 10.2.1.1. U.S.
- 10.2.1.2. Canada
- 10.2.2. By Product Type
- 10.2.3. By Application
- 10.2.4. By Indication
- 10.2.5. By End User
- 10.3. Market Attractiveness Analysis
- 10.3.1. By Country
- 10.3.2. By Product Type
- 10.3.3. By Application
- 10.3.4. By Indication
- 10.3.5. By End User
- 10.4. Key Takeaways
- 11. Latin America Virology Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
- 11.2.1. By Country
- 11.2.1.1. Brazil
- 11.2.1.2. Mexico
- 11.2.1.3. Rest of Latin America
- 11.2.2. By Product Type
- 11.2.3. By Application
- 11.2.4. By Indication
- 11.2.5. By End User
- 11.3. Market Attractiveness Analysis
- 11.3.1. By Country
- 11.3.2. By Product Type
- 11.3.3. By Application
- 11.3.4. By Indication
- 11.3.5. By End User
- 11.4. Key Takeaways
- 12. Europe Virology Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
- 12.2.1. By Country
- 12.2.1.1. Germany
- 12.2.1.2. U.K.
- 12.2.1.3. France
- 12.2.1.4. Spain
- 12.2.1.5. Italy
- 12.2.1.6. Rest of Europe
- 12.2.2. By Product Type
- 12.2.3. By Application
- 12.2.4. By Indication
- 12.2.5. By End User
- 12.3. Market Attractiveness Analysis
- 12.3.1. By Country
- 12.3.2. By Product Type
- 12.3.3. By Application
- 12.3.4. By Indication
- 12.3.5. By End User
- 12.4. Key Takeaways
- 13. East Asia Virology Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
- 13.2.1. By Country
- 13.2.1.1. China
- 13.2.1.2. Japan
- 13.2.1.3. South Korea
- 13.2.2. By Product Type
- 13.2.3. By Application
- 13.2.4. By Indication
- 13.2.5. By End User
- 13.3. Market Attractiveness Analysis
- 13.3.1. By Country
- 13.3.2. By Product Type
- 13.3.3. By Application
- 13.3.4. By Indication
- 13.3.5. By End User
- 13.4. Key Takeaways
- 14. South Asia & Pacific Virology Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
- 14.2.1. By Country
- 14.2.1.1. India
- 14.2.1.2. Thailand
- 14.2.1.3. Indonesia
- 14.2.1.4. Malaysia
- 14.2.1.5. Singapore
- 14.2.1.6. Australia
- 14.2.1.7. New Zealand
- 14.2.1.8. Rest of South Asia & Pacific
- 14.2.2. By Product Type
- 14.2.3. By Application
- 14.2.4. By Indication
- 14.2.5. By End User
- 14.3. Market Attractiveness Analysis
- 14.3.1. By Country
- 14.3.2. By Product Type
- 14.3.3. By Application
- 14.3.4. By Indication
- 14.3.5. By End User
- 14.4. Key Takeaways
- 15. MEA Virology Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
- 15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
- 15.2.1. By Country
- 15.2.1.1. GCC Countries
- 15.2.1.2. South Africa
- 15.2.1.3. Israel
- 15.2.1.4. Rest of MEA
- 15.2.2. By Product Type
- 15.2.3. By Application
- 15.2.4. By Indication
- 15.2.5. By End User
- 15.3. Market Attractiveness Analysis
- 15.3.1. By Country
- 15.3.2. By Product Type
- 15.3.3. By Application
- 15.3.4. By Indication
- 15.3.5. By End User
- 15.4. Key Takeaways
- 16. Key Countries Virology Market Analysis
- 16.1. U.S.
- 16.1.1. Pricing Analysis
- 16.1.2. Market Share Analysis, 2021
- 16.1.2.1. By Product Type
- 16.1.2.2. By Application
- 16.1.2.3. By Indication
- 16.1.2.4. By End User
- 16.2. Canada
- 16.2.1. Pricing Analysis
- 16.2.2. Market Share Analysis, 2021
- 16.2.2.1. By Product Type
- 16.2.2.2. By Application
- 16.2.2.3. By Indication
- 16.2.2.4. By End User
- 16.3. Brazil
- 16.3.1. Pricing Analysis
- 16.3.2. Market Share Analysis, 2021
- 16.3.2.1. By Product Type
- 16.3.2.2. By Application
- 16.3.2.3. By Indication
- 16.3.2.4. By End User
- 16.4. Mexico
- 16.4.1. Pricing Analysis
- 16.4.2. Market Share Analysis, 2021
- 16.4.2.1. By Product Type
- 16.4.2.2. By Application
- 16.4.2.3. By Indication
- 16.4.2.4. By End User
- 16.5. Germany
- 16.5.1. Pricing Analysis
- 16.5.2. Market Share Analysis, 2021
- 16.5.2.1. By Product Type
- 16.5.2.2. By Application
- 16.5.2.3. By Indication
- 16.5.2.4. By End User
- 16.6. U.K.
- 16.6.1. Pricing Analysis
- 16.6.2. Market Share Analysis, 2021
- 16.6.2.1. By Product Type
- 16.6.2.2. By Application
- 16.6.2.3. By Indication
- 16.6.2.4. By End User
- 16.7. France
- 16.7.1. Pricing Analysis
- 16.7.2. Market Share Analysis, 2021
- 16.7.2.1. By Product Type
- 16.7.2.2. By Application
- 16.7.2.3. By Indication
- 16.7.2.4. By End User
- 16.8. Spain
- 16.8.1. Pricing Analysis
- 16.8.2. Market Share Analysis, 2021
- 16.8.2.1. By Product Type
- 16.8.2.2. By Application
- 16.8.2.3. By Indication
- 16.8.2.4. By End User
- 16.9. Italy
- 16.9.1. Pricing Analysis
- 16.9.2. Market Share Analysis, 2021
- 16.9.2.1. By Product Type
- 16.9.2.2. By Application
- 16.9.2.3. By Indication
- 16.9.2.4. By End User
- 16.10. China
- 16.10.1. Pricing Analysis
- 16.10.2. Market Share Analysis, 2021
- 16.10.2.1. By Product Type
- 16.10.2.2. By Application
- 16.10.2.3. By Indication
- 16.10.2.4. By End User
- 16.11. Japan
- 16.11.1. Pricing Analysis
- 16.11.2. Market Share Analysis, 2021
- 16.11.2.1. By Product Type
- 16.11.2.2. By Application
- 16.11.2.3. By Indication
- 16.11.2.4. By End User
- 16.12. South Korea
- 16.12.1. Pricing Analysis
- 16.12.2. Market Share Analysis, 2021
- 16.12.2.1. By Product Type
- 16.12.2.2. By Application
- 16.12.2.3. By Indication
- 16.12.2.4. By End User
- 16.13. India
- 16.13.1. Pricing Analysis
- 16.13.2. Market Share Analysis, 2021
- 16.13.2.1. By Product Type
- 16.13.2.2. By Application
- 16.13.2.3. By Indication
- 16.13.2.4. By End User
- 16.14. Thailand
- 16.14.1. Pricing Analysis
- 16.14.2. Market Share Analysis, 2021
- 16.14.2.1. By Product Type
- 16.14.2.2. By Application
- 16.14.2.3. By Indication
- 16.14.2.4. By End User
- 16.15. Indonesia
- 16.15.1. Pricing Analysis
- 16.15.2. Market Share Analysis, 2021
- 16.15.2.1. By Product Type
- 16.15.2.2. By Application
- 16.15.2.3. By Indication
- 16.15.2.4. By End User
- 16.16. Malaysia
- 16.16.1. Pricing Analysis
- 16.16.2. Market Share Analysis, 2021
- 16.16.2.1. By Product Type
- 16.16.2.2. By Application
- 16.16.2.3. By Indication
- 16.16.2.4. By End User
- 16.17. Singapore
- 16.17.1. Pricing Analysis
- 16.17.2. Market Share Analysis, 2021
- 16.17.2.1. By Product Type
- 16.17.2.2. By Application
- 16.17.2.3. By Indication
- 16.17.2.4. By End User
- 16.18. Australia
- 16.18.1. Pricing Analysis
- 16.18.2. Market Share Analysis, 2021
- 16.18.2.1. By Product Type
- 16.18.2.2. By Application
- 16.18.2.3. By Indication
- 16.18.2.4. By End User
- 16.19. New Zealand
- 16.19.1. Pricing Analysis
- 16.19.2. Market Share Analysis, 2021
- 16.19.2.1. By Product Type
- 16.19.2.2. By Application
- 16.19.2.3. By Indication
- 16.19.2.4. By End User
- 16.20. GCC Countries
- 16.20.1. Pricing Analysis
- 16.20.2. Market Share Analysis, 2021
- 16.20.2.1. By Product Type
- 16.20.2.2. By Application
- 16.20.2.3. By Indication
- 16.20.2.4. By End User
- 16.21. South Africa
- 16.21.1. Pricing Analysis
- 16.21.2. Market Share Analysis, 2021
- 16.21.2.1. By Product Type
- 16.21.2.2. By Application
- 16.21.2.3. By Indication
- 16.21.2.4. By End User
- 16.22. Israel
- 16.22.1. Pricing Analysis
- 16.22.2. Market Share Analysis, 2021
- 16.22.2.1. By Product Type
- 16.22.2.2. By Application
- 16.22.2.3. By Indication
- 16.22.2.4. By End User
- 17. Market Structure Analysis
- 17.1. Competition Dashboard
- 17.2. Competition Benchmarking
- 17.3. Market Share Analysis of Top Players
- 17.3.1. By Regional
- 17.3.2. By Product Type
- 17.3.3. By Application
- 17.3.4. By Indication
- 17.3.5. By End User
- 18. Competition Analysis
- 18.1. Competition Deep Dive
- 18.1.1. Thermo Fisher Scientific, Inc.
- 18.1.1.1. Overview
- 18.1.1.2. Product Portfolio
- 18.1.1.3. Profitability by Market Segments
- 18.1.1.4. Sales Footprint
- 18.1.1.5. Strategy Overview
- 18.1.1.5.1. Marketing Strategy
- 18.1.1.5.2. Product Strategy
- 18.1.1.5.3. Channel Strategy
- 18.1.2. Merck KGaA
- 18.1.2.1. Overview
- 18.1.2.2. Product Portfolio
- 18.1.2.3. Profitability by Market Segments
- 18.1.2.4. Sales Footprint
- 18.1.2.5. Strategy Overview
- 18.1.2.5.1. Marketing Strategy
- 18.1.2.5.2. Product Strategy
- 18.1.2.5.3. Channel Strategy
- 18.1.3. Eurofins Scientific S.E.
- 18.1.3.1. Overview
- 18.1.3.2. Product Portfolio
- 18.1.3.3. Profitability by Market Segments
- 18.1.3.4. Sales Footprint
- 18.1.3.5. Strategy Overview
- 18.1.3.5.1. Marketing Strategy
- 18.1.3.5.2. Product Strategy
- 18.1.3.5.3. Channel Strategy
- 18.1.4. QIAGEN N.V.
- 18.1.4.1. Overview
- 18.1.4.2. Product Portfolio
- 18.1.4.3. Profitability by Market Segments
- 18.1.4.4. Sales Footprint
- 18.1.4.5. Strategy Overview
- 18.1.4.5.1. Marketing Strategy
- 18.1.4.5.2. Product Strategy
- 18.1.4.5.3. Channel Strategy
- 18.1.5. Becton, Dickinson and Company
- 18.1.5.1. Overview
- 18.1.5.2. Product Portfolio
- 18.1.5.3. Profitability by Market Segments
- 18.1.5.4. Sales Footprint
- 18.1.5.5. Strategy Overview
- 18.1.5.5.1. Marketing Strategy
- 18.1.5.5.2. Product Strategy
- 18.1.5.5.3. Channel Strategy
- 18.1.6. Danaher Corporation
- 18.1.6.1. Overview
- 18.1.6.2. Product Portfolio
- 18.1.6.3. Profitability by Market Segments
- 18.1.6.4. Sales Footprint
- 18.1.6.5. Strategy Overview
- 18.1.6.5.1. Marketing Strategy
- 18.1.6.5.2. Product Strategy
- 18.1.6.5.3. Channel Strategy
- 18.1.7. NeoGenomics, Inc.
- 18.1.7.1. Overview
- 18.1.7.2. Product Portfolio
- 18.1.7.3. Profitability by Market Segments
- 18.1.7.4. Sales Footprint
- 18.1.7.5. Strategy Overview
- 18.1.7.5.1. Marketing Strategy
- 18.1.7.5.2. Product Strategy
- 18.1.7.5.3. Channel Strategy
- 18.1.8. Biolog, Inc.
- 18.1.8.1. Overview
- 18.1.8.2. Product Portfolio
- 18.1.8.3. Profitability by Market Segments
- 18.1.8.4. Sales Footprint
- 18.1.8.5. Strategy Overview
- 18.1.8.5.1. Marketing Strategy
- 18.1.8.5.2. Product Strategy
- 18.1.8.5.3. Channel Strategy
- 18.1.9. IEH Laboratories & Consulting Group
- 18.1.9.1. Overview
- 18.1.9.2. Product Portfolio
- 18.1.9.3. Profitability by Market Segments
- 18.1.9.4. Sales Footprint
- 18.1.9.5. Strategy Overview
- 18.1.9.5.1. Marketing Strategy
- 18.1.9.5.2. Product Strategy
- 18.1.9.5.3. Channel Strategy
- 18.1.10. VWR Corporation
- 18.1.10.1. Overview
- 18.1.10.2. Product Portfolio
- 18.1.10.3. Profitability by Market Segments
- 18.1.10.4. Sales Footprint
- 18.1.10.5. Strategy Overview
- 18.1.10.5.1. Marketing Strategy
- 18.1.10.5.2. Product Strategy
- 18.1.10.5.3. Channel Strategy
- 18.1.11. Altogen Labs
- 18.1.11.1. Overview
- 18.1.11.2. Product Portfolio
- 18.1.11.3. Profitability by Market Segments
- 18.1.11.4. Sales Footprint
- 18.1.11.5. Strategy Overview
- 18.1.11.5.1. Marketing Strategy
- 18.1.11.5.2. Product Strategy
- 18.1.11.5.3. Channel Strategy
- 18.1.12. STERIS Plc.
- 18.1.12.1. Overview
- 18.1.12.2. Product Portfolio
- 18.1.12.3. Profitability by Market Segments
- 18.1.12.4. Sales Footprint
- 18.1.12.5. Strategy Overview
- 18.1.12.5.1. Marketing Strategy
- 18.1.12.5.2. Product Strategy
- 18.1.12.5.3. Channel Strategy
- 18.1.13. Dynatec Labs
- 18.1.13.1. Overview
- 18.1.13.2. Product Portfolio
- 18.1.13.3. Profitability by Market Segments
- 18.1.13.4. Sales Footprint
- 18.1.13.5. Strategy Overview
- 18.1.13.5.1. Marketing Strategy
- 18.1.13.5.2. Product Strategy
- 18.1.13.5.3. Channel Strategy
- 18.1.14. Wickham Laboratories Ltd.
- 18.1.14.1. Overview
- 18.1.14.2. Product Portfolio
- 18.1.14.3. Profitability by Market Segments
- 18.1.14.4. Sales Footprint
- 18.1.14.5. Strategy Overview
- 18.1.14.5.1. Marketing Strategy
- 18.1.14.5.2. Product Strategy
- 18.1.14.5.3. Channel Strategy
- 18.1.15. Charles River Laboratories Inc.
- 18.1.15.1. Overview
- 18.1.15.2. Product Portfolio
- 18.1.15.3. Profitability by Market Segments
- 18.1.15.4. Sales Footprint
- 18.1.15.5. Strategy Overview
- 18.1.15.5.1. Marketing Strategy
- 18.1.15.5.2. Product Strategy
- 18.1.15.5.3. Channel Strategy
- 19. Assumptions & Acronyms Used
- 20. Research Methodology
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.